Natera, Inc. (NTRA)

Market Cap	13.11B
Revenue (ttm)	1.21B
Net Income (ttm)	-365.46M
Shares Out	122.80M
EPS (ttm)	-3.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	713,391
Open	108.63
Previous Close	108.50
Day's Range	106.40 - 108.75
52-Week Range	36.90 - 108.75
Beta	1.38
Analysts	Strong Buy
Price Target	100.50 (-5.6%)
Earnings Date	May 9, 2024

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplanta...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 3,293
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA

Financial Performance

In 2023, Natera's revenue was $1.08 billion, an increase of 31.99% compared to the previous year's $820.22 million. Losses were -$434.80 million, -20.63% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price forecast is $100.5, which is a decrease of -5.60% from the latest price.

Price Target

$100.5

(-5.60% downside)

Analyst Consensus: Strong Buy